鹽酸普樂沙福作用機(jī)制 - Medchemexpress - MCE中國

1、Product Data SheetPlerixafor octahydrochlorideCat. No.: HY-50912CAS No.: 155148-31-5分式: CHClN分量: 794.47作靶點: CXCR; Virus Protease作通路: GPCR/G Protein; Immunology/Inflammation; Anti-infection儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 H2O : 100 mg/mL (125.87 mM; Need

2、 ultrasonic)DMSO : 50 mg/kg; LD50, mouse and rat, IVinjection: 5.2 mg/kg.PROTOCOLCell Assay 2 U87MG cells are seeded in 96-well plates at the density of 6103 cells in 200 L/well and treated with CXCL12,Plerixafor or with peptide R, as described in the previous “Treatments” section. MTT (5 g/mL) is a

3、dded at each timepoint (24, 48, 72 h) during the final 2 h of treatment. After removing cell medium, 100 L DMSO are added andoptical densities measured at 595 nm with a LT-4000MS Microplate Reader. Measurements are made in triplicatesfrom three independent experiments2.MCE has not independently conf

4、irmed the accuracy of these methods. They are for reference only.Animal Mice3Administration 34 Male C57bl/6 mice (6-7 weeks old, weighing 20 g) are used. The animals are acclimated to the housing environment,which is SPF and had a temperature of 22C and a 12h/12h light/dark cycle for a week. Then, t

5、hey are randomlydivided into following experimental groups, with 8 mice in each group: normal (no specific intervention),UUO+AMD3100 (mice received UUO surgery and 2 mg/kg AMD3100), and UUO+PBS (mice received UUO surgeryand the same volume of PBS). AMD3100 and PBS are administered via intraperitonea

6、l injection every day untilsacrifice.Rats4The CXCR4 antagonist, AMD3100 dissolved in H2O, is delivered in the type 2 diabetic sand rat model at a dose of 6mg/kg per day for 8 weeks. In complementary studies, the effect of CXCR4 antagonism (AMD3100 6mg/kg/d) onregulatory T cell numbers is examined. F

7、or these studies, AMD3100 or vehicle is delivered via minipump for a periodof one week.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Adv Funct Mater. 2020 Feb. Cell Mol Immunol. 2019 Jul 18. Oncogene. 2019 Jun;38(25):5021-5037. Brain Behav

8、 Immun. 2017 Jan;59:322-332. Cell Death Dis. 2017 Jan 19;8(1):e2560.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7ligands.

9、 J Immunol. 2009 Sep 1;183(5):3204-11.2. Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a humanglioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.Page 2 of 3 www.MedChemE3. Yang J, et al. Continuous AMD3100

10、Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11(2):e0149926.4. Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10(7):e0133616.McePdfHeightCaution: Product has not been fully validated for medical ap